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Abstract
Contrast-induced nephropathy is an injury to the kidney occurring as a result of exposure to
intravascular contrast media. It results in both short- and long-term adverse events including
mortality. Since treatment of the injury after it has occurred is ineffective, efforts to prevent the
injury are the focus of investigators and clinicians alike. In this commentary, the pathogenesis and
clinical relevance of contrast-induced nephropathy are reviewed. Prophylactic strategies are
discussed with a focus on the use of meta-analysis of small single-center trials.
Introduction
Contrast-induced nephropathy (CIN) is an acute kidney
injury associated with both short- and long-term adverse
outcomes, including the need for renal replacement ther-
apy, increased length of hospital stay, major cardiac
adverse events, and mortality [1-3]. Since there is no effec-
tive therapy once injury has occurred, prevention is the
cornerstone for all patients at risk for acute kidney injury.
There is a small but growing body of evidence that preven-
tion of the acute kidney injury is associated with a reduc-
tion in those later adverse outcomes. The article by Meier
and colleagues, published this month in BMC Medicine,
examines the prophylactic treatment of CIN using intrave-
nous bicarbonate for prevention of CIN and the impact of
such therapy on long term adverse events[4].
CIN involves at least two complementary pathophysio-
logic processes. First, contrast media is directly toxic to
renal tubule cells, leading to mitochondrial dysfunction,
generation of reactive oxygen species (ROS), and pro-
grammed cell death [5,6]. Second, contrast media reduces
medullary blood flow further compromising a very tenu-
ous balance between oxygen consumption and tissue oxy-
gen availability in this critical area of the kidney. It is this
part of the kidney that contains the last part of the proxi-
mal tubule and the thick ascending limb of Henle where
a large proportion of sodium reabsorption occurs through
active transport[7].
Current limitations of diagnosis of CIN
Our ability to diagnose CIN is limited by the lack of an
appropriately sensitive and specific marker of kidney
injury. Neutrophil gelatinase associated lipocalin, kidney
injury molecule-1, interleukin-18 and other markers are
currently being evaluated as reliable indicators of injury
and predictors of adverse outcomes [8]. Until such valida-
tion occurs, changes in kidney function, specifically
glomerular filtration rate (GFR), remain our only means
of diagnosing CIN. In clinical practice, changes in GFR are
estimated by absolute or relative changes in serum creati-
nine, that is, increases of ≥0.5 mg/dl or ≥25%, respec-
tively, occurring 48 to 72 hours after contrast exposure.
Unfortunately, changes in serum creatinine can occur for
reasons other than a decrease in GFR and thus are not spe-
cific for a decrease in GFR. Furthermore, because of the
time lag between a fall in GFR and a rise in creatinine, the
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timing of creatinine measurement following contrast
exposure can affect the sensitivity of the test [9]. Cystatin
C has been advocated as a more sensitive marker of a fall
in GFR [10-12].
Current status of prevention therapies
A variety of failed approaches has led to skepticism regard-
ing our ability to effectively prevent the injury causing
CIN. Systemically administered vasodilators, such as
dopamine agonists, adenosine antagonists, prostagland-
ins, and endothelin antagonists, have been disappointing
despite the rationale behind their use [13]. Antioxidants,
such as N-acetylcysteine, ascorbic acid, and bicarbonate,
have enjoyed initial enthusiasm based upon single-center
trials [14-16]. However, when considering data presented
at society meetings and the increasing number of pub-
lished negative trials, enthusiasm has waned and even
meta-analyses have not found significant efficacy [17]. It
is in this context that the article by Meier et al., published
this month in BMC Medicine [4], is particularly valuable as
it explores reasons for the heterogeneity in trial results.
Bicarbonate therapy for prevention of CIN
Bicarbonate therapy was initially explored because the
generation of ROS is pH dependent through the Haber-
Weiss reaction [18]. It was argued that systemic alkaliniza-
tion might reduce ROS generation and minimize the sub-
sequent kidney injury. Subsequent studies with
acetazolamide, which alkalinizes the urine while causing
systemic acidification, showed that it is the urinary space
that is the important site at which this pH effect acts [19].
Alkalinization of the urinary space is achieved very
quickly with infusion of sodium bicarbonate because nor-
mally there is little bicarbonate in the urine. Even a small
increase in serum bicarbonate of 1 to 2 mEq/liter will
result in the 'dumping' of bicarbonate into the urine in
most patients. Such a change in serum is easily obtained
with the infusion rates recommended in most of the CIN
prevention trials [14,20].
Bicarbonate therapy is readily available, inexpensive, and
safe. The question is whether it is efficacious for preven-
tion of CIN. Some single-center trials have found bicarbo-
nate therapy to be efficacious while others have not. A
previous metaanalysis of a small number of trials found
bicarbonate to be beneficial only when not combined
with other prophylaxis [21]. This heterogeneity in results
leaves the physician confused at best and apathetic to pre-
vention strategies at worst. Differences in selection criteria
of patients, definition of outcome (CIN), protocols for
administration of therapy, use of concomitant therapies,
timing of follow-up serum samples, and so on may
account for this heterogeneity. The article by Meier et al.
tries to unravel some of these issues by looking at specific
subsets of patients. For example, evidence of publication
bias was found which the authors tried to overcome by
including unpublished trials presented at major clinical
meetings. Of particular clinical interest was the finding
that bicarbonate therapy was most effective in patients
who experienced urgent or emergency contrast exposure.
Presumably this selects a group of patients who are less
likely to receive any other form of prophylaxis for CIN.
This is of great potential importance for the emergency
room and cardiac catheterization laboratory. Bicarbonate
therapy was also most effective in those receiving low
osmolality contrast media compared with iso-osmolality
contrast media. Low osmolality contrast is increasingly
chosen because of its safety, lower costs, and higher iodine
content [22].
Future directions
CIN needs to be redefined using markers of kidney injury
that are sensitive, specific, and predictive of adverse out-
comes. This will enable researchers to better address the
question of how to prevent and/or treat this condition in
the future. The most important question to be answered is
whether prevention of kidney injury results in a change in
short- and long-term adverse outcomes. Some prevention
strategies have been associated with a reduction in long-
term adverse events [23,24], while others have not [25-
27]. The meta-analyses by Meier et al. found that despite a
reduction in the incidence of CIN, bicarbonate therapy
had no benefit on the need for dialysis or mortality. No
matter how available, inexpensive, and safe a therapy, to
find an important role in clinical therapeutics, it must
improve the 'downstream' adverse outcomes, an as yet
elusive goal for the prevention and treatment of CIN.
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